Effect of cancer on platelets

Cancer Treatment and Research

Volumn 148, Issue , 2009, Pages 17-30

  Green, David L ^a   Karpatkin, Simon ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HIRUDIN; THROMBIN; TUMOR PROTEIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PREVENTION; CELL ADHESION; DEEP VEIN THROMBOSIS; DORMANCY; ESOPHAGUS CANCER; HUMAN; HYPERCOAGULABILITY; LABORATORY TEST; LUNG CANCER; METASTASIS; NEOPLASM; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; THROMBOCYTE FUNCTION; THROMBOSIS; TUMOR CELL; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; MOUSE; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; THROMBOCYTE; THROMBOPHILIA; VASCULAR ENDOTHELIUM;

ANIMALS; ASPIRIN; BLOOD PLATELETS; CELL ADHESION; CLINICAL TRIALS AS TOPIC; ENDOTHELIUM, VASCULAR; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBIN; THROMBOPHILIA;

EID: 71949088295     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-79962-9_2     Document Type: Review

References (96)

1. Trousseau A. Plegmasie alba dolens. Clinique Medical de Hotel-Dieu de Paris, London. New Syndenham Society 1865;3:94.
2. Billroth T. Lectures on surgical pathology and therapeutics: a handbook for students and practitioners. New Syndenham Society:1877-8.
3. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107(23 Suppl 1):I17-21.
4. Rickles F. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006;35(1-2):103-10.
5. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975;6(1):61-4.
6. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006;10(5):355-62.
7. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484-8.
8. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343(25):1846-50.
9. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285-91.
10. Shulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anti-coagulation trial. NEJM 2000;3432:1953.
11. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med 1964;114:497-500.
12. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979;71(1):10-6.
13. Sack JGH, Levin, J, Bell WR. Trepusseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic and therapeutic features. Medicine 1977;56:1-37.
14. Slichter SJ, Harker LA. Hemostasis in malignancy. Ann N Y Acad Sci 1974;230:252-61.
15. Lyman GH, Bettigole RE, Robson E, Ambrus JL, Urban H. Fibrinogen kinetics inpatients with neoplastic disease. Cancer 1978;41(3):1113-22.
16. Rickles F, Edwards R. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
17. Gale AJ, Gordon, SG. Update on tumor cell procoagulant factors. Acta Haematol 2001;106:25-32.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
19. Sporn MB. The war on cancer. Lancet 1996;347(9012):1377-81.
20. Gasic G, Gasic T, Stewart C. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968;61:46-52.
21. Pearlstein E, Ambrogio C, Karpatkin S. Effect of anti-platelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma and B16 amelanotic melanoma tumor cells in mice. Cancer Res 1984;44:3884-7.
22. Wood S. Experimental studies of the intravascular dissemination of ascetic V2 carcinoma cells in the rabbit with special reference to fibrinogen and fibrinolytic agents. Bull Schweiz Med Wiss 1964;20:92.
23. D.L. Green and S. Karpatkin
24. Jones J, Wallace A, Fraser E. Sequence of events in experimental and electron microscopic observations. J Natl Cancer Inst 1971;46:493-504.
25. Sindelar W, Tralka T, Ketcham A. Electron microscope observations on formation of pulmonary metastases. J Surg Res 1975;18:137-61.
26. Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer 1973;11(3):704-18.
27. Pearlstein E, Salk PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci USA 1980;77(7):4336-9.
28. Camerer E, Qazi A, Duong D, Cornelissen I, Rommel A, Coughlin S. Platelets, proteaseactivated receptors, and fibrinogen in hematogenous metastasis. Blood 2004;104:397-401.
29. Crissman JD, Hatfield JS, Menter DG, Sloane B, Honn KV. Morphological study of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. Cancer Res 1988;48(14):4065-72.
30. Morimoto K, Satoh-Yamaguchi K, Hamaguchi A, Inoue Y, et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene 2008;27(3):264-73.
31. Kojima H, Kanada H, Shimizu S, Kasama E, et al. CD226 mediates platelet and megakaryocytic cell adhesion to vascular endothelial cells. J Biol Chem 2003; 278(38):36748-53.
32. Fidler I. Metastases: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 1970;45:773-82.
33. Nieswandt B, Hafner M, Echtenacher B, Mannel D. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295-300.
34. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105(1):178-85.
35. Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood 1984;63(1):55-63.
36. Karpatkin S, Ambrogio C, Pearlstein E. Lack of effect of in vivo prostacyclin on the development of pulmonary metastases in mice following intravenous injection of CT26 colon carcinoma, Lewis lung carcinoma, or B16 amelanotic melanoma cells. Cancer Res 1984;44(9):3880-3.
37. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988;81:1012-9.
38. Trikha M, Zhou Z, Timar J, et al. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002;62(10):2824-33.
39. Terraube V, Pendu R, Baruch D, Gebbink MFBG. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 2006; 4(3):519-26.
40. Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 2003;100(24):14205-10.
41. Biggerstaff J, Seth N, Amirkhosravi A, et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exper Metastas 1999;17:723-30.
42. Felding-Habermann B, Habermann R, Saldivar E, Ruggeri ZM. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem 1996;271:5892-900.
43. Effect of Cancer on Platelets 27
44. McCarty O, Mousa S, Bray P, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 2000;96:1789-97.
45. Kim Y, Borsig L, Varki N, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 1998;95:9325-30.
46. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001;98(6):3352-7.
47. Terranova V, Williams J, Liotta L. Modulation of metastatic activity of melanoma cells by laminin and fibronectin. Science 1984;226:982-4.
48. Cheresh D, Smith W, Cooper H, et al. A novel vitronectin receptor integrin (avbx) is responsible for distinct adhesive properties of carcinoma cells. Cell 1989;57:59-69.
49. Kramer R, Marks N. Identification of integrin collagen receptors on human melanoma cells. J Biol Chem 1989;264:4684-8.
50. Roberts D, Sherwood J, Ginsburg V. Platelet thrombospondin mediates attachment and spreading of human melanoma cells. J Cell Biol 1987;104:131-9.
51. Klepfish A, Greco MA, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer 1993;53(6):978-82.
52. Carney D, Stiernberg J, Fenton J. Initiation of proliferative events by human -thrombin requires both receptor binding and enzymatic activity. J Cell Biochem 1984;26:181-95.
53. Chen L, Buchanan J. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975;72:131-5.
54. Gospodarowicz D, Brown K, Birdwell C, Zetter B. Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. J Cell Biol 1978;77:774-88.
55. Caunt M, Huang YQ, Brooks PC, Karpatkin S. Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J Thromb Haemost 2003;1(10):2097-102.
56. Nierodzik M, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991;87:229-36.
57. Dardik R, Savion N, Kaufmann Y, Varon D. Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIa. Br J Cancer 1998;77:2069-75.
58. Nierodzik ML, Bain RM, Liu L-X, Shivji M, Takeshita K, Karpatkin S. Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumour tyrosine phosphorylation. Br J Haematol 1996;92:452-7.
59. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4:909-14.
60. Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2(7):395-402.
61. Nierodzik M, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998;92(10):3694-700.
62. Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res 2006;66(8):4125-32.
63. Hu L, Roth JM, Brooks P, Ibrahim S, Karpatkin S. Twist is required for thrombininduced tumor angiogenesis and growth. Cancer Res 2008;68(11).
64. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117(7):927-39.
65. Hu L, Roth JM, Brooks P, Luty J, Simon K. Thrombin up-regulates Cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res 2008;68(12). 28 D.L. Green and S. Karpatkin
66. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding and spontaneous metastasis. Blood 2004;104:2746-51.
67. Mueller B, Reisfeld R, Edgington T, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992;89:832-6.
68. Fisher E, Ruf W, Mueller B. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995;55:1629-32.
69. Zacharski L, Memoli V, Morain W, Schlaeppi J-M, Rousseau S. Cellular localization of enzymatically-active thrombin in intact tissue by hirudin binding. Thromb Haemostas 1995;73:793-7.
70. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96(10):3302-9.
71. Offermanns S, ToombsCF,HuYH, SimonMI. Defective platelet activation inGq-deficient mice. Nature 1997;389:183-6.
72. Spaet TH. Vascular factors in the pathogenesis of hemorrhagic syndromes. Blood 1952;7(6):641-52.
73. Gimbrone MA Jr, Aster RH, Cotran RS, Corkery J, Jandl JH, Folkman J. Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature 1969;222(5188):33-6.
74. Kitchens CS, Weiss L. Ultrastructural changes of the endothelium associated with thrombocytopenia. Blood 1975;46:567-78.
75. Kitchens CS, Pendergast JF. Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration. Blood 1986;67:203-6.
76. Pintucci G, Froum S, Pinnell J, Mignatti P, Rafii S, Green D. Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost 2002;88(5):834-42.
77. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 1998;125(6):1252-7.
78. Miyazono K, Takaku F. Platelet-derived growth factors. Blood Reviews 1989;3(4):269-76.
79. Liu Y, Wada R, Yamashita T, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000;106(8):951-61.
80. Paik JH, Skoura A, Chae SS, et al. Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev 2004;18(19):2392-403.
81. Boucharaba A, Serre CM, Gres S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114(12):1714-25.
82. Brill A, Elinav H, Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res 2004;63(2):226-35.
83. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005;67(1):30-8.
84. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA 2001;98(11):6470-5.
85. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008;111(3):1227-33.
86. Cervi D, Yip T-T, Bhattacharya N, Podust VN, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008;111(3):1201-7.
87. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995;92(16):7450-4.
88. Frenette PS, Denis CV, Weiss L, et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000;191(8):1413-22.
89. Jin DK, Shido K, Kopp HG, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006;12(5):557-67.
90. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998;352(9142):1775-7.
91. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3(12 Pt 1):2187-90.
92. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325(23):1593-6.
93. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53(6):1322-7.
94. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 2006;17(7):871-88.
95. Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C. No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules'' Group. Cancer 1993;71(5):1741-5.
96. Miller G, Bauer K, Howarth D, Cooper J, Humphries S, Rosenberg R. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004;2:2107-14.